Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.59 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.54 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.52 |
| ▸ | CXCR4 | P61073 | 7/20 | 0.51 |
| ▸ | GNRHR | P30968 | 1/20 | 0.51 |
| ▸ | GLP1R | P43220 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | MC4R | P32245 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSH | P09668 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29391874 | 0.96 | C5AR1 (0.59) | C5AR1KISS1RABCC2CXCR4GNRHR | |
| SCHEMBL29520158 | 0.92 | C5AR1 (0.61) | C5AR1KISS1RABCC2CXCR4GNRHR | |
| SCHEMBL29390323 | 0.92 | ABCC2 (0.63) | C5AR1ABCC2GNRHRPTGS1 | |
| SCHEMBL29391110 | 0.92 | C5AR1 (0.64) | C5AR1KISS1RABCC2CXCR4GNRHR | |
| SCHEMBL29942618 | 0.90 | C5AR1 (0.64) | C5AR1KISS1RABCC2CXCR4GNRHR | |
| SCHEMBL30271248 | 0.90 | C5AR1 (0.64) | C5AR1KISS1RABCC2CXCR4GNRHR | |
| SCHEMBL22288702 | 0.89 | KISS1R (0.57) | C5AR1KISS1RABCC2CXCR4GNRHR | |
| SCHEMBL22288705 | 0.89 | KISS1R (0.57) | C5AR1KISS1RABCC2CXCR4GNRHR | |
| SCHEMBL29425255 | 0.89 | C5AR1 (0.68) | C5AR1KISS1RCXCR4GLP1RMC4R | |
| SCHEMBL34464914 | 0.89 | GNRHR (0.60) | C5AR1KISS1RABCC2CXCR4GNRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509435-B2 | Compounds for selective binding to estrogen receptors alpha/beta relative to GPER/GPR30 and methods of treating disease states and conditions mediated through these receptors | UNM RAINFOREST INNOVATIONS (US) | 2025-12-30 | — | — | US | disclosed |
| US-20230039502-A1 | COMPOUNDS FOR SELECTIVE BINDING TO ESTROGEN RECEPTORS ALPHA/BETA RELATIVE TO GPER/GPR30 AND METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS | UNM RAINFOREST INNOVATIONS | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509435-B2 | Compounds for selective binding to estrogen receptors alpha/beta relative to GPER/GPR30 and methods of treating disease states and conditions mediated through these receptors | GPER1, ESR2, ESRRG | C5AR1 2206/4885KISS1R 100/4885ABCC2 2017/4885 |
| US-20230039502-A1 | COMPOUNDS FOR SELECTIVE BINDING TO ESTROGEN RECEPTORS ALPHA/BETA RELATIVE TO GPER/GPR30 AND METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS | GPER1, GPR35, GPR34 | C5AR1 3213/4885KISS1R 93/4885ABCC2 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.